RM RMTG Regenerative Medical Technology Group Loading... : Investor Sentiment and Bull/Bear Views

The author argues RMTG is set up for another run into its Q3 report, noting Q2 revenue of $4.02M, $565k operating income, 64% gross margin and $6.6M for the half, all verifiable in filings. With the market cap still under $2M and the stock at $0.037 on almost no volume, the author expects another ~$4M quarter and says a return to 6-7 cents would be an easy double from here, similar to last quarter's move from $0.06 to $0.12. The author also highlights the BKFC regenerative-medicine partnership and ringside presence at the Prudential Center on October 17 as brand exposure. Main stated risk is debt, which the author dismisses as manageable if cash generation and servicing continue.

Author took a starter position in OTC biotech RMTG, whose Cellgenics peptide division and ISSCA physician-training ecosystem are riding the post-Ozempic regenerative medicine boom. Revenue jumped from $5.1m for all of 2025 to $6.66m in H1 2026, with Q2 at $4.02m versus $984k a year earlier, driven by both product sales and physician training, while dilution stayed under 5% over the past year. The author cites debt and interest expense as the main risk and is still evaluating before taking a larger position. Chart shows higher highs and lows with accumulation in the .08 range.

The author argues RMTG's newly detailed ISSCA AI Clinical Intelligence Platform is a real product, not vague AI talk, with a reasoning corpus of 1.6 million longitudinal health records and over 10,000 clinical studies. The commercial model adds four revenue channels (SaaS subscriptions via the existing physician network, patient longevity memberships, conference-based sales, and an ISSCA AI certification program) on top of existing training and product revenue, creating high-margin recurring revenue. The author cites Q2 revenue of $4.02M with $565K operating income and expects Q3 to be the tell, seeing close to $8M in revenue with potential upside if AI platform traction builds in the 30+ country, thousands-of-doctors network. Main risk implied is whether the SaaS and membership channels actually gain traction.